Navigation Links
Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
Date:11/10/2009

CAMBRIDGE, Mass. and TOKYO, Nov. 10 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand. Linaclotide is currently in Phase 3 clinical development in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Under the terms of the agreement, Astellas would pay Ironwood $75 million in upfront and precommercial milestones, including a $30 million licensing fee, as well as escalating royalties on linaclotide sales. Astellas will lead clinical development in Japan and be responsible for all activities and expenses relating to clinical development, regulatory approval, and commercialization in the above mentioned territory.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO )

"We are pleased to initiate a great partnership with Ironwood," said Masafumi Nogimori, Astellas' president and chief executive officer. "This collaboration fits well with our existing gastrointestinal franchise in Japan, and I'm excited to deliver linaclotide to the Asian territory. I strongly believe that Astellas will maximize the potential product value of linaclotide with our proven capabilities."

"This collaboration continues Ironwood's strategy to form partnerships to develop and commercialize linaclotide in the top three pharmaceutical markets: the U.S., Europe, and Japan, while enabling Ironwood to retain potentially fifty percent of the long-term global value of linaclotide in those key regions, should linaclotide meet our sales expectations," said Peter Hecht, Ironwood's chief executive officer. "Astellas has strong capabilities for delivering linaclotide
'/>"/>

SOURCE Ironwood Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
5. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
6. Ironwood Announces Linaclotide European Licensing Agreement with Almirall
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Marsha Fanucci Joins Ironwood Board of Directors
9. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance (CEA) ... series designed to educate children about the most common neurological ... Medikidz Explain Epilepsy comic series tells a fictional story ... middle school while living with epilepsy. "Despite ... is still so much misinformation and lack of awareness out ...
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans believe ... is a serious public health and safety issue in ... a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse ... with this very serious health situation facing our country," ...
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS International, ... Manufacturing Intelligence , today announces Infusion Chicago, ... event will be held Oct. 9-10, 2014, at ... designed to showcase the necessity for implementing a ... and Manufacturing Intelligence to gain insight into production ...
Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2
(Date:8/22/2014)... 2014 Until now, those with leg or ... walkers to keep mobile. Thanks to an inventor from Suffolk, ... effective. , He developed a prototype for the patent-pending SUPPORT ... or foot but provide comfort and reduce pain for those ... it is also convenient and easy to install on the ...
(Date:8/22/2014)... 265,000 Danes are acutely admitted to medical departments with ... and Aarhus University Hospital now shows that many of ... are sent home again without receiving a diagnosis of ... "Naturally, there is no need for a diagnosis if ... a serious illness. So some patients will always be ...
(Date:8/22/2014)... intolerance. However, these are two entirely different mechanisms that ... not digest lactose properly because they lack an enzyme ... much more dangerous cow milk allergy, however, the body,s ... antibodies. , According to statistics, about two to three ... milk allergy. Less adults are diagnosed with the disease. ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 The ALS ... the ALS Center at Allegheny Health Network ... Center, based at Allegheny General Hospital (AGH), is the ... the ALS Association for meeting the highest levels of ... amyotrophic lateral sclerosis (ALS), often referred to as Lou ...
(Date:8/22/2014)... 21, 2014 (HealthDay News) -- The air in American ... Protection Agency reported Thursday. Significant progress has been ... air in recent decades, the agency said in a ... nearly 60 percent reduction in mercury from human sources ... benzene, and an 84 percent fall in lead, which ...
Breaking Medicine News(10 mins):Health News:Assistive Device for Walking Invented by InventHelp Client (VBL-501) 2Health News:Many patients are discharged without a diagnosis 2Health News:Scientists uncover why major cow milk allergen is actually allergenic 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... Sept. 14 The following is a,Statement by Oscar S. Wyatt, Jr.: "I,ve seen some ... politicians who want to,return those funds received from me, please return them in the form of ... ... Medical Foundation ...
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) management will be ... 43rd Annual Meeting of the European,Association for the Study ... a.m. PT / 1:30 p.m. CET local time in ... and recordings will be made,available following the event. The ...
... defects, U.S. experts say , , FRIDAY, Sept. 14 (HealthDay News) ... women since the federal government mandated folate fortification to prevent ... is enough -- or too much. , A new study ... finds that the number of women of childbearing age who ...
... Most people looking for tax advice,usually go to ... right? Here,s more on a new report that shows ... are actually not seeing the pros,trained in their field. ... Registered journalists can access video, audio, text, ...
... Blue Cross and Blue,Shield Association (BCBSA) convened a ... D.C., to discuss how insurers, doctors and hospitals,are ... safety.,Representatives from the Premier Inc. healthcare alliance, Duke ... Alabama, and WellPoint, Inc.,participated in the event. ...
... between the two protective treatments , FRIDAY, Sept. 14 (HealthDay ... a pill called dabigatran etexilate (DE) is just as effective ... blood clots after total hip replacement surgery. , As reported ... study included almost 3,500 hip replacement patients who received either ...
Cached Medicine News:Health News:Women's Folic Acid Levels Improving 2Health News:Women's Folic Acid Levels Improving 3Health News:Women's Folic Acid Levels Improving 4Health News:Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 2Health News:Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 3Health News:Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 4Health News:Pill Equals Injection in Preventing Clots After Hip Replacement 2
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With tubular ...
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: